HeartSciences Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andrew Simpson
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 550 Reserve Street Southlake TX United States of America 76092-1552
- IPO Date
- Jun 16, 2022
- CIK
- 0001468492
- Website
- heartsciences.com
- Similar Companies
- Business
- HeartSciences Inc. is a medical technology company specializing in artificial intelligence (AI)-powered electrocardiography (ECG) solutions to enable earlier detection of heart disease. Its core products include the MyoVista wavECG device, a resting 12-lead electrocardiograph that utilizes AI and continuous wavelet transform (CWT) signal processing to provide diagnostic information on left ventricular diastolic dysfunction and other cardiac conditions; MyoVista Insights, a cloud-native software platform that hosts AI-ECG algorithms on an ECG hardware-agnostic basis; and proprietary AI algorithms designed to detect cardiac dysfunction including impaired cardiac relaxation and structural heart disease. HeartSciences’ technology aims to expand the clinical utility of traditional ECG testing, particularly in frontline and point-of-care settings. Founded in 2007 and headquartered in Southlake, Texas, HeartSciences operates primarily in the United States within the healthcare and medical device sectors. The company targets healthcare providers and institutions requiring advanced diagnostic tools to identify heart disease earlier and more accurately. Recent major developments include receiving FDA Breakthrough Device designation for its aortic stenosis detection ECG algorithm; nearing submission for FDA 510(k) clearance of the MyoVista wavECG device; launching the MyoVista Insights cloud platform in 2025 to modernize ECG data management; securing CMS reimbursement approval at $128 per AI-ECG test; expanding its intellectual property portfolio to 44 granted patents globally; and strategically advancing commercialization efforts with expectations for revenue generation in 2026 pending regulatory approvals. The company was formerly known as Heart Test Laboratories, Inc. until its name change in October 2024.
HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network
HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
Analyzing Rennova Health (OTCMKTS:RNVA) & HeartSciences (NASDAQ:HSCS)
HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
Comparing 10x Genomics (NASDAQ:TXG) and HeartSciences (NASDAQ:HSCS)
Hinge Health (NYSE:HNGE) versus HeartSciences (NASDAQ:HSCS) Financial Analysis
HeartSciences' MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
University of West England Adopts HeartSciences' MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
Cibolo Health Designates HeartSciences' MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
HeartSciences (NASDAQ:HSCS) & Health Catalyst (NASDAQ:HCAT) Critical Analysis
Market Today: Ford axes Lightning, iRobot bankrupt, Nvidia-China chips
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1
HeartSciences (HSCS) to Release Quarterly Earnings on Monday
Reviewing Hims & Hers Health (NYSE:HIMS) and HeartSciences (NASDAQ:HSCS)
HeartSciences (NASDAQ:HSCS) and Bullfrog AI (NASDAQ:BFRG) Critical Analysis